1st Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Clin Exp Ophthalmol. 2010 Oct;38(7):683-7. doi: 10.1111/j.1442-9071.2010.02304.x. Epub 2010 Jul 9.
The aim of the study was to evaluate long-term results of autologous serum treatment for recurrent corneal erosions.
In this prospective single-centre study, 33 eyes of 33 patients (21 male and 12 female) were treated with autologous serum eye drops for recurrent corneal erosions. Mean age of the patients was 49.3 ± 9.8 standard deviation (range 24-73) years. All subjects had failed to respond to other treatments. Autologous serum drops were administered for a 6-month period: six times daily for the first 3 months and four times daily for the remaining 3 months. Detailed informed consent was obtained from the entire patient group before the study.
The mean follow-up period was 30 ± 6.3 standard deviation (range 12-48) months. None of the patients experienced a recurrence while under treatment. Twenty-eight patients (85%) had complete healing of erosions with no relapses of the disease over the whole follow-up period. Five patients (15%) presented a single recurrence 3-12 months after the end of the treatment. No sight-threatening complications were reported over the follow up. There was no statistically significant difference in the best spectacle-corrected visual acuity values (t(stat) = 2.1, F = 0.096, degree of freedom = 40,166, P < 0.41) or in the intraocular pressure measurements (P < 0.38) between the pre- and post-treatment patient groups.
Autologous serum drops proved to be a safe and efficient treatment modality for patients with recurrent corneal erosion syndrome as observed through a long-term follow up.
本研究旨在评估自体血清治疗复发性角膜糜烂的长期疗效。
在这项前瞻性单中心研究中，33 名患者（21 名男性和 12 名女性）的 33 只眼接受了自体血清滴眼剂治疗复发性角膜糜烂。患者的平均年龄为 49.3 ± 9.8 标准差（范围 24-73）岁。所有患者均对其他治疗方法无反应。自体血清滴剂治疗 6 个月：前 3 个月每天 6 次，后 3 个月每天 4 次。在研究之前，从整个患者组获得了详细的知情同意书。
平均随访时间为 30 ± 6.3 标准差（范围 12-48）个月。治疗期间，无患者出现复发。28 名患者（85%）的糜烂完全愈合，整个随访期间无疾病复发。5 名患者（15%）在治疗结束后 3-12 个月出现单次复发。在随访期间未报告任何威胁视力的并发症。治疗前后患者组的最佳矫正视力值（t(stat) = 2.1，F = 0.096，自由度= 40.166，P < 0.41）或眼压测量值（P < 0.38）均无统计学差异。
通过长期随访，自体血清滴眼剂被证明是治疗复发性角膜糜烂综合征患者的一种安全有效的治疗方法。
